S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Jarrow Formulas Expands Supplement Line With Protein and Aging Support

With over 70% of Americans increasing their daily protein intake, Jarrow Formulas is shifting the focus from quantity to efficacy. The California-based company announced the launch of Gut & Protein Optimizer and NMN 300 mg today, two new products aimed at improving nutrient absorption and cellular energy levels.

Jarrow Formulas Expands Supplement Line With Protein and Aging Support
Photo: Bio & News

The Gut & Protein Optimizer addresses the limitations of high-protein diets by combining Mycosha, a probiotic for microbiome health, with the digestive enzyme blend Prohydrolase. This formula targets the breakdown of dietary proteins into amino acids, an approach particularly marketed toward consumers managing weight or utilizing GLP-1 medications. Priced at $29.99, the supplement is designed to maximize the metabolic value of the protein consumers already ingest.

Simultaneously, the company is entering the longevity market with its NMN 300 mg supplement. By providing a clinically studied 300 mg dose of nicotinamide mononucleotide, the product acts as a precursor to NAD+, a metabolite essential for mitochondrial function that naturally declines with age. According to Rebekah Lyle, CMO of Vytalogy Wellness, these additions reflect a broader consumer shift toward proactive health management. Both products are available through Jarrow.com, Amazon, and select retailers.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!